ERICH6 Variant 1: Potential Drug Target and Neurodegenerative Diseases

Target Name: ERICH6

NCBI ID: G131831

ERICH6

ERICH6 Variant 1: Potential Drug Target and Neurodegenerative Diseases

ERICH6 (ERICH6 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. Its full name is ERICH6, and it is a member of the ERICH6 family.

ERICH6 variant 1 is a protein with a molecular weight of 21.9 kDa. Its structure is slightly different from ERICH6 variant 2, but they both have conserved amino acid sequences.

ERICH6 variant 1 plays an important role in apoptosis, cell proliferation, cell migration, cell invasion and tumorigenesis. In tumorigenesis, the expression level of ERICH6 variant 1 usually increases with tumor growth.

Because ERICH6 variant 1 plays an important role in a variety of cancers, it is considered a potential drug target. Researchers are exploring ERICH6 variant 1 as a drug target to treat various cancers.

ERICH6 variant 1 also plays an important role in neurological diseases. For example, it has been linked to neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

In addition, ERICH6 variant 1 is also associated with liver disease. The liver is an important metabolic organ in the human body and the main site of drug metabolism. Therefore, the expression level of ERICH6 variant 1 in liver diseases has received great attention.

ERICH6 variant 1 is a very important protein that plays an important role in maintaining human health. With the continuous development of science and technology, researchers will continue to explore the role of ERICH6 variant 1 in the treatment of various diseases.

Protein Name: Glutamate Rich 6

The "ERICH6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERICH6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets